Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials

Published on Dec 1, 2019in Clinical Colorectal Cancer3.176
· DOI :10.1016/j.clcc.2019.07.009
Julien Taieb46
Estimated H-index: 46
(Paris V: Paris Descartes University),
M. Geissler11
Estimated H-index: 11
+ 7 AuthorsMarie-Rose Peeters43
Estimated H-index: 43
Abstract Background There is no standardised assessment of symptomatic events in metastatic colorectal cancer (mCRC), despite disease symptoms impacting treatment decisions. Data from 3 first-line panitumumab in mCRC trials were retrospectively analysed to assess whether early tumour shrinkage (ETS) and depth of response (DpR) are associated with time to occurrence of tumour-related symptoms. Patients and Methods Patients with RAS wild-type mCRC from PRIME, PEAK and study ‘314 were included. ETS was defined as a reduction of ≥ 30% in the sum-of-the-longest-diameters of lesions at 8 weeks. DpR was calculated as maximum percentage change in tumour size from baseline to nadir. The proportion of patients who developed symptoms (including a composite symptomatic endpoint) during study treatment was calculated. Results Overall, 659 patients were analysed. Onset of symptoms was delayed in patients with ETS ≥ 30% versus ETS Conclusion Both ETS and DpR were associated with delayed onset of symptoms in RAS wild-type mCRC patients. Treatments with high cytoreductive potential may delay symptom development. Identifiers PRIME NCT00364013; PEAK NCT00819780; study ‘314 NCT00508404.
  • References (26)
  • Citations (0)
📖 Papers frequently viewed together
6 Citations
9 Citations
13 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Herbert Hurwitz (Durham University)H-Index: 60
#2Benjamin R. TanH-Index: 25
Last. Johanna C. BendellH-Index: 25
view all 14 authors...
3 CitationsSource
#1Freddie Ian Bray (IARC: International Agency for Research on Cancer)H-Index: 88
#2Jacques Ferlay (IARC: International Agency for Research on Cancer)H-Index: 66
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 106
view all 6 authors...
3,723 CitationsSource
#1Marie-Rose PeetersH-Index: 43
#2Timothy J. Price (University of Adelaide)H-Index: 39
Last. Salvatore Siena (University of Milan)H-Index: 74
view all 10 authors...
6 CitationsSource
#1Chiara Cremolini (UniPi: University of Pisa)H-Index: 29
#2Carlotta Antoniotti (UniPi: University of Pisa)H-Index: 15
Last. A Falcone (UniPi: University of Pisa)H-Index: 19
view all 22 authors...
19 CitationsSource
#1Julien Taieb (Paris V: Paris Descartes University)H-Index: 46
#2Fernando RiveraH-Index: 39
Last. Marie-Rose PeetersH-Index: 43
view all 10 authors...
Purpose To report exploratory analyses of early tumour shrinkage (ETS) and depth of response (DpR) in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC), receiving the first-line treatment in three randomised panitumumab trials.
7 CitationsSource
#1Marisa WalkerH-Index: 106
#2William Bruce Wong (Genentech)H-Index: 4
Last. Lee S. SchwartzbergH-Index: 41
view all 5 authors...
Background Treatment options for advanced nonsquamous non-small cell lung cancer (NSCLC) in the first line include platinum-based doublet therapy with or without bevacizumab. This study examined efficacy outcomes and patient reported outcomes (PROs) in a community oncology patient sample.
6 CitationsSource
#1Dominik Paul ModestH-Index: 22
#2Sebastian StintzingH-Index: 29
Last. V. HeinemanH-Index: 57
view all 17 authors...
// Dominik Paul Modest 1, 2 , Sebastian Stintzing 1, 2 , Ludwig Fischer von Weikersthal 3 , Thomas Decker 4 , Alexander Kiani 5 , Ursula Vehling-Kaiser 6 , Salah-Eddin Al-Batran 7 , Tobias Heintges 8 , Christoph Kahl 9 , Gernot Seipelt 10 , Frank Kullmann 11 , Werner Scheithauer 12 , Markus Moehler 13, 14 , Julian Walter Holch 1, 2 , Jobst Christian von Einem 1, 2 , Swantje Held 15 and Volker Heinemann 1, 2 1 Department of Medicine III, University Hospital, LMU Munich, Munich, Germany 2 German C...
15 CitationsSource
Purpose To report planned final overall (OS) and progression-free survival (PFS) analyses from the phase II PEAK trial (NCT00819780).
21 CitationsSource
#1Meinolf KarthausH-Index: 21
Last. C.-H. KoehneH-Index: 49
view all 13 authors...
Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
11 CitationsSource
#1Eric Van Cutsem (Katholieke Universiteit Leuven)H-Index: 122
#2Andrés Cervantes (University of Valencia)H-Index: 56
Last. Dirk ArnoldH-Index: 8
view all 47 authors...
The clinical outcome for patients with metastatic CRC (mCRC) has improved greatly over the last 20 years. These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particula...
599 CitationsSource
Cited By0